Cyberonics Refocuses Sales And Marketing Effort On Epilepsy Treatment
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics will emphasize the epilepsy indication of its VNS vagus nerve stimulation implant in the wake of reimbursement difficulties that have hindered marketing of its depression indication
You may also be interested in...
LivaNova Reenters Medicare Fray Seeking VNS Depression Coverage
The US Centers for Medicare and Medicaid Services opened a national coverage reconsideration analysis for vagus nerve stimulation for treatment-resistant depression on May 30, 11 years after it declined to cover the treatment for this indication.
Cyberonics Fails In Final Appeal For VNS Depression Medicare Coverage
Cyberonics was unsuccessful in a last-ditch effort to win Medicare coverage for its VNS Therapy System for treatment-resistant depression. HHS’ Departmental Appeals Board backed CMS’ 2007 decision that the depression indication is not reasonable and necessary.
Cyberonics' Ambitious 5-Year Plan: Double Sales With New VNS Components
Cyberonics aims to double its sales to $320 million over the next five years by improving and adding new features to its VNS Therapy vagus nerve stimulation implant and entering new markets like Japan